.jetcityimage/iStock Content by means of Getty Images Morgan Stanley has actually picked Eli Lilly (NYSE: LLY) as its best biopharma selection for 2025 as well as ranked yet another 9 titles in the room as overweight. The expenditure financial institution pointed out in a details that it remains to believe “diabesity is actually set to end up being.